Needham & Company Cuts Target on Vivus (VVUS), Adjusts Qsymia Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Not Expecting E.U. Approval for Vivus' (VVUS) Qsiva, Could be a Plus for Orexigen (OREX) - Analyst
September 21, 2012 12:19 PM EDTShares Vivus (NASDAQ: VVUS) are getting slapped 11 percent Friday following news that the company expects EU regulators to recommending against... More
VIVUS (VVUS) Says EMA CHMP May Recommend Against MAA for Qsiva
September 21, 2012 7:05 AM EDTVIVUS, Inc. (Nasdaq: VVUS) announced that based on preliminary feedback from the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP), the company expects an opinion recommending against approval of the Marketing Authorization Application (MAA) for Qsiva (phentermine/topiramate ER) for the treatment of obesity.... More
